Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients
Authors:
- Young Ju WonYWYoung Ju Won
- Byung Gun LimBLByung Gun Lim
- Dong Kyu LeeDLDong Kyu Lee
- Heezoo KimHKHeezoo Kim
- Myoung Hoon KongMKMyoung Hoon Kong
- Il Ok LeeILIl Ok Lee
Open Access
- 1 August 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (34) , e4678
Abstract
Previous studies have shown that sugammadex, a modified γ-cyclodextrin, is a well-tolerated agent for the reversal of neuromuscular blockade (NMB) induced by a steroidal neuromuscular blocking drug in adult patients. However, its use has not been reviewed in pediatric patients. The aim of this meta-analysis was to evaluate the efficacy and safety of sugammadex in the reversal of rocuronium-induced NMB during surgery under general anesthesia in pediatric patients. A literature search was performed using the Pubmed, EMBASE: Drugs and pharmacology, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. Analysis was conducted using RevMan 5.3. Data collected from different trials were pooled; the weighted mean difference or the pooled risk ratio and the corresponding 95% confidence interval (CI) were used for analysis, and heterogeneity (I 2) assessment was performed. Six randomized controlled trials comparing 253 pediatric patients (age range, 2–18 years) were included in the final analysis. The mean time taken to reach a train-of-four ratio of ≥0.9 was significantly shorter in the sugammadex groups (2 and 4 mg/kg) than in the control group (neostigmine or placebo), although the heterogeneity was high. The weighted mean differences of the 2 and 4 mg/kg sugammadex groups were −7.15 (95% CI: −10.77 to −3.54; I 2 = 96%; P = 0.0001) and −17.32 (95% CI: −29.31 to −5.32; I 2 = 98%; P = 0.005), respectively. The extubation time in the sugammadex group was shorter than that in the control group; the weighted mean difference of the sugammadex group was −6.00 (95% CI: −11.46 to −0.53; I 2 = 99%; P = 0.03). There was no significant difference between the groups in terms of the incidence of postanesthetic adverse events; the pooled risk ratio was 0.67 (95% CI: 0.27–1.71; I 2 = 59%; P = 0.41). We suggest that sugammadex is fast and effective in reversing rocuronium-induced NMB in pediatric patients. Although there was no evidence of a higher incidence of adverse events with sugammadex compared to that with neostigmine or placebo, much more data regarding the safety of sugammadex in pediatric patients may be still required.Keywords
This publication has 29 references indexed in Scilit:
- Sugammadex as a reversal agent for neuromuscular block: an evidence-based reviewCore Evidence, 2013
- Efficacy and safety of a sugammadex dose of 4 mg/kg in early reversal of a deep neuromuscular block rocuronium-induced in infants and children: a case seriesEuropean Journal of Anaesthesiology, 2013
- Introduction of sugammadex as standard reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcomeIndian Journal of Anaesthesia, 2013
- Sugammadex reversal efficacy and security vs neostigmine in the rocuronium - induced neuromuscular blockade in paediatric patientsEuropean Journal of Anaesthesiology, 2011
- Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluationBritish Journal of Anaesthesia, 2010
- Neuromuscular block and current treatment strategies for its reversal in childrenPediatric Anesthesia, 2010
- Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockadeCochrane Database of Systematic Reviews, 2009
- Reversal of Rocuronium-induced Neuromuscular Blockade with Sugammadex in Pediatric and Adult Surgical PatientsAnesthesiology, 2009
- Neuromuscular Effects of Rocuronium During Sevoflurane, Isoflurane, and Intravenous AnesthesiaAnesthesia & Analgesia, 1998
- Neuromuscular Effects of Rocuronium During Sevoflurane, Isoflurane, and Intravenous AnesthesiaAnesthesia & Analgesia, 1998